medRxiv preprint doi: https://doi.org/10.1101/2021.08.05.21261528; this version posted August 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . IL-2 stromal signatures dissect immunotherapy response groups in non- small cell lung cancer (NSCLC) James Monkman1, Honesty Kim2, Aaron Mayer2, Ahmed Mehdi3, Nicholas Matigian3, Marie Cumberbatch4, Milan Bhagat4, Rahul Ladwa5,6, Scott N Mueller7, Mark N Adams1, Ken O’Byrne1,5*, Arutha Kulasinghe1,6,8* 1. Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Brisbane, QLD, Australia 2. Enable Medicine, Menlo Park, CA, USA 3. QFAB Bioinformatics, The University of Queensland, Brisbane, QLD, Australia. 4. Tristar Technologies Group, Rockville, MD, USA 5. Princess Alexandra Hospital, Brisbane, QLD, Australia 6. University of Queensland, Faculty of Medicine, Brisbane, QLD, Australia 7. Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia. 8. University of Queensland, Institute of Molecular Biosciences, QLD, Australia *Corresponding Authors: Dr Arutha Kulasinghe:
[email protected]; Prof Ken O’Byrne:
[email protected] Address: Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, 37 Kent Street, Woolloongabba, QLD 4102, Australia. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.